No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Chemicals - Specialty
AnteoTech Limited develops, manufactures, commercializes, and distributes products for clean energy technology and life science markets primarily in Australia, Asia, Europe, and North America. The company’s products include AnteoBind, a metal-ion complex-based activation technology that offers an alternative to conventionally used chemistries for the life sciences industry; AnteoBind NXT solution for the development of diagnostic tests; AnteoBind Micro and Micro Kit, a micro-particle-based assay development and bioseparation; AnteoBind Sub-Micron, Particle-based assay development, and bioseparation; AnteoBind Biosensor, a planar solid phase assay development; Activation Kit Multiplex Microspheres, an immunoassay development; and Nano Kit, a nanoparticle-based lateral flow assay development and bioseparation. It also provides AnteoX, an additive that reinforces battery binders that enhance performance of silicon containing anodes; and Ultranode, an ultra-high silicon anode design to offer high performance for lithium-ion batteries. In addition, the company offers contract services. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited is headquartered in Eight Mile Plains, Australia.
www.anteotech.comNo one on the platform currently holds ADO.AX.
No tracked institution reports a position in ADO.AX as of their last filing.
No one on the platform has traded ADO.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Analyst estimates unavailable for this ticker.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $3M | +211.1% | $0.00 | $0.00–$0.00 | — | 1 |
| 2028 | $4M | +50.0% | $0.00 | $0.00–$0.00 | — | 1 |
| 2029 | $8M | +97.6% | $0.00 | $0.00–$0.00 | — | 0 |
| 2030 | $15M | +85.5% | $0.00 | $0.00–$0.00 | — | 0 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| ADO.AXAnteoTech Limited | $0.02 | -5.26% | $59M | — |
| AGN.AXArgenica Therapeutics Ltd | $0.17 | +2.94% | $22M | — |
| CYP.AXCynata Therapeutics Limited | $0.01 | +0.00% | $3M | — |
| EYE.AXNova Eye Medical Limited | $0.13 | -3.70% | $37M | — |
| IIQ.AXINOVIQ Ltd | $0.17 | +0.00% | $24M | — |
| NOX.AXNoxopharm Limited | $0.07 | +0.00% | $23M | — |
Source: Financial Modeling Prep · peers by sector/industry
| NSB.AXNeuroScientific Biopharmaceuticals Limited | $0.06 | -4.84% | $23M | — |